Introduction Seronegative enteropathies (SNEs) represent a challenging group of disorders characterised by villous atrophy with negative coeliac serology. They include both seronegative coeliac disease (SNCD) and a broad spectrum of non-coeliac enteropathies such as infections, immune disorders, and drug-related causes.
Introduction
Seronegative enteropathies (SNEs) represent a challenging group of disorders characterised by villous atrophy with negative coeliac serology. They include both seronegative coeliac disease (SNCD) and a broad spectrum of non-coeliac enteropathies such as infections, immune disorders, and drug-related causes. Their rarity, overlapping features, and lack of specific biomarkers make diagnosis difficult in routine practice.
Problem Statement
The biggest clinical issue is misdiagnosis. Many patients with non-coeliac enteropathies are incorrectly labelled as seronegative coeliac disease and started on a gluten-free diet. This leads to unnecessary lifelong dietary restriction, delayed diagnosis of the true underlying condition, and risk of poor outcomes. Differentiating SNCD from other causes of villous atrophy remains complex due to overlapping clinical and histological findings.
Summary
This review provides a practical framework for evaluating and managing SNEs. The key principle is systematic exclusion of non-coeliac causes before diagnosing SNCD. A definitive diagnosis of SNCD requires clinical and histological response to a gluten-free diet after other etiologies are ruled out.
Non-coeliac enteropathies must be actively considered, including infections, immune-mediated diseases, medications, and malignancies. Accurate diagnosis is essential, as these conditions often require entirely different treatments.
Long-term outcomes vary significantly. While appropriately treated SNCD has a favorable prognosis, misdiagnosed or untreated non-coeliac enteropathies may lead to serious complications and increased mortality.
Overall, this review emphasizes a structured diagnostic approach, cautious use of gluten-free diet, and tailored management strategy to improve patient outcomes and avoid diagnostic pitfalls.
Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...
Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...
Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...
Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...
Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...
Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.